The fund, the company’s second in less than two years, will be used to invest in the hot space where AI is being used to develop new, lifesaving drugs.
Reed Albergotti is the Technology Editor at Semafor, where he covers the latest developments in the tech industry. He is the co-author of "Wheelmen," a book about the Lance Armstrong doping scandal, and is an avid cyclist. Albergotti's reporting focuses on emerging technologies, AI, and the intersection of tech and business.